In a victory for the U.S. Food and Drug Administration, a 9th U.S. Circuit Court of Appeals panel ruled Friday that the agency can regulate stem cell treatments by two Southern California centers as drugs under federal law.
The decision is a major victory for government regulators in their legal showdowns with medical clinics across the country that offer treatments using patients' own stem cells. An 11th U.S. Circuit Court of Appeals panel ruled in June 2021 for the FDA agai...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In